Earnings Releases·Nov 5, 2026, 4:01 PM ET

Celldex Therapeutics — Third Quarter 2026 Earnings Summary

Reported $37,000 revenue for the nine months ended September 30, 2026, a decline from $1.4 million in the prior year period, while net loss widened to $227.7 million ($3.06 per share) from $177.4 million ($2.67 per share) year-to-date.
Cash and marketable securities decreased to $650.3 million as of September 30, 2026, from $717.6 million in June 2026, though management confirms sufficient liquidity to fund operations through 2028.
Barzolvolimab Phase 3 studies (EMBARQ-CSU1 and EMBARQ-CSU2) met all primary and key secondary endpoints with best-in-disease results, supporting a planned Biologics License Application (BLA) submission for chronic spontaneous urticaria in 2027.
The Phase 2 study in prurigo nodularis was discontinued due to pathogenic driver concerns, while CDX-622 showed positive Phase 1 results and is advancing in asthma trials; additional barzolvolimab indications are expected by year-end.